Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 9/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138113 | 0.88 | MAP2K1 (0.36) | MAP2K1MAP2K2 | |
| SCHEMBL6137904 | 0.85 | SOS1 (0.38) | MEN1KMT2ATDP1 | |
| SCHEMBL6137880 | 0.85 | MEN1 (0.36) | IDO1MAP2K1MEN1KMT2ATDP1 | |
| SCHEMBL6137820 | 0.80 | KMT2A (0.34) | IDO1MAP2K1MEN1KMT2ATDP1 | |
| SCHEMBL6137780 | 0.79 | IDO1 (0.38) | IDO1MAP2K1MEN1KMT2ATDP1 | |
| SCHEMBL6137948 | 0.78 | IDO1 (0.39) | IDO1MAP2K1MEN1KMT2ATDP1 | |
| SCHEMBL6138124 | 0.78 | IDO1 (0.36) | IDO1MAP2K1MEN1KMT2ATDP1 | |
| SCHEMBL6137963 | 0.78 | IDO1 (0.36) | IDO1MAP2K1MEN1KMT2ATDP1 | |
| SCHEMBL6138258 | 0.77 | IDO1 (0.33) | IDO1MAP2K1MEN1KMT2ATDP1 | |
| SCHEMBL6137923 | 0.77 | IDO1 (0.35) | IDO1MAP2K1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1144394-B1 | 1-HETEROCYCLE SUBSTITUTED DIARYLAMINES | WARNER LAMBERT CO (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6545030-B1 | Treating proliferative diseases, the sequelae of a stroke or heart failure, xenograft rejection, osteoarthritis, HIV, rheumatoid arthritis, cystic fibrosis, hepatomegaly, shock,cardiomegaly, Alzheimer's disease, diabetes | WARNER-LAMBERT COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-20030004193-A1 | 1-Heterocycle substituted diarylamines | BARRETT STEPHEN DOUGLAS (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1202732-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001005391-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004193-A1 | 1-Heterocycle substituted diarylamines | IDH3A, CCNA1, HCCS | IDO1 244/4885MAP2K1 3800/4885MEN1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.